Embedded Files
CRAFT YOUR BUSINESS, AND REDEFINE YOUR PERFORMANCE WITH DELVEINSIGHT!
ASCO: axi-cel in ZUMA-1
Abstract No : 8012
Abstract Type : Oral Abstract Session
Indication : Diffused Large B-Cell Lymphoma (DLBCL)
Intervention : Yescarta
Company : Kite, a Gilead Company
Technology : CAR T Cell Therapy
Based on this limited sample size, reTx with axi-cel may have clinical efficacy, although transient, in some pts, especially those who achieve CR with 1st Tx. CAR T cell expansion and severe CRS and NEs may be attenuated at reTx. Further studies with additional pts are needed to confirm these results.
View More: https://www.delveinsight.com/asco-conference/article/zuma-1
GSK: Cell Therapy and Next-generation Immuno-oncology
At this year’s ASCO meeting, they will showcase presentations on investigational therapies, including belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer.
View More: https://www.delveinsight.com/asco-conference/article/gsk-cell-therapy-next-generation-immuno-oncology
IMbrave150 TRIAL of Atezolizumab
IMbrave150 demonstrated statistically significant and clinically meaningful improvement in both OS and PFS with atezo + bev vs sor in pts with unresectable HCC who have not received prior systemic therapy. Pts achieved CRs regardless of poor prognostic factors or etiology. Atezo + bev may be a practice-changing treatment for pts with unresectable HCC.
View More: https://www.delveinsight.com/asco-conference/article/imbrave150
ASCO: KEYNOTE-204
Abstract No : 8005
Abstract Type : Oral Abstract Session
Indication : Hodgkin’s Lymphoma (HL)
Intervention : Pembrolizumab
Company : Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
Technology : Immunocheckpoint
In pts with R/R cHL, pembro was superior to BV and demonstrated statistically significant and clinically meaningful improvement in PFS across all subgroups, with safety consistent with previous reports. Pembro monotherapy should be standard of care for this pt population with R/R/cHL.
View More: https://www.delveinsight.com/asco-conference/article/NCT02684292
ASCO: INO-5401 + INO-9012 with Cemiplimab
Abstract No : 2514
Abstract Type : Oral Abstract Session
Indication : Glioblastoma Multiforme
Intervention : INO-5401 and INO-9012 + Cemiplimab
Company : Inovio Pharma
Technology : T cell therapy/Monoclonal Antibody
INO-5401 + INO-9012 in combination with cemiplimab and RT/TMZ has an acceptable safety profile, is immunogenic and may show a survival advantage in patients with newly-diagnosed GBM.
View Report: https://www.delveinsight.com/asco-conference/article/NCT03491683
Page updated
Report abuse